ReviewBest practice & research. Clinical rheumatology2017
A review on SLE and malignancy.
Review in Best practice & research. Clinical rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Unraveling the connection and pathogenesis of systemic lupus erythematosus and thyroid cancer: integrative meta-analysis, Mendelian randomization, and transcriptomic insights.Clinical rheumatology · 2026Pooled it
- Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis.Clinical rheumatology · 2019Pooled it
- The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis.Arthritis research & therapy · 2018Pooled it
- Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.Lupus science & medicine · 2021Trial
- Application of BCMA CAR-T in systemic lupus erythematosus.Clinical rheumatology · 2026Article
- Article
- Malignancies in lupus nephritis: a retrospective cohort study on epidemiology and risk factors.Lupus science & medicine · 2026Article
- Pathogenic and Clinical Relevance of Serum IL-17A and TNF-α in Systemic Lupus Erythematosus.International journal of molecular sciences · 2026Article
- Review
- Development and validation of a multiple myeloma diagnostic model based on systemic lupus erythematosus-associated genes and identification of specific genes.Discover oncology · 2025Article
- Association Between Lupus Nephritis and Renal Clear-Cell Carcinoma: A Case Report and Review of the Literature.Cureus · 2025Article
- Circulating CD8 + LGALS9 + T Cell Population Exhibiting Low Cytotoxic Characteristics are Decreased in Patients with Systemic Lupus Erythematosus.Immunologic research · 2024Article
- Comparison of Clinical and Laboratory Characteristics in Lupus Nephritis vs. Non-Lupus Nephritis Patients-A Comprehensive Retrospective Analysis Based on 921 Patients.Journal of clinical medicine · 2024Article
- Elevated levels of IL-12/IL-23p40 in Nova Scotia Duck Tolling Retrievers with autoimmune disease and lymphoma.Scientific reports · 2024Article
- Higher mortality risk from gynaecological neoplasms and non-Hodgkin's lymphoma in patients with systemic lupus erythematosus: an observational study from the Spanish National Registry.Lupus science & medicine · 2024Observational
- SLE and multiple myeloma: an underlooked link? A review of case reports from the last decade.Journal of medicine and life · 2024Review
- Exploring the Molecular Mechanisms and Shared Gene Signatures Between Systemic Lupus Erythematosus and Bladder Urothelial Carcinoma.International journal of general medicine · 2024Article
- Construction of competing endogenous RNA networks in systemic lupus erythematosus by integrated analysis.Frontiers in medicine · 2024Article
- The interconnected roles of TRIM21/Ro52 in systemic lupus erythematosus, primary Sjögren's syndrome, cancers, and cancer metabolism.Cancer cell international · 2023Review
- Clinicopathological prognostic characteristics and long‑term outcomes of patients with breast cancer and collagen disorder in comparison to those without collagen disorder.Oncology letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by autoantibody production, complement activation, and immune complex deposition. It predominantly affects young and middle-aged women. While improvements in the diagnosis and treatment of SLE have altered prognosis, morbidity and mortality rates remain higher than the general population. In addition to renal injury, cardiovascular disease, and infection, malignancy is known to be a significant cause of death in this population. There is increasing evidence to suggest that patients with SLE have a slightly higher overall risk of malignancy. The risk of malignancy in SLE is of considerable interest because the immune and genetic pathways underlying the pathogenesis of SLE and the immunosuppressant drugs (ISDs) used in its management may mediate this altered risk. Our current understanding of these and other risk factors and the implications for treating SLE and screening for malignancy is still evolving. This review summarizes the association between SLE and malignancy. The first section discusses the risk of overall and site-specific malignancies in both adult- and pediatric-onset SLE. Next, we evaluate the risk factors and possible mechanisms underlying the link between malignancy and SLE, including the use of ISDs, presence of certain SLE-related autoantibodies, chronic immune dysregulation, environmental factors, and shared genetic susceptibility. Finally, we review guidelines regarding cancer screening and vaccination for human papilloma virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.